Marshall J. Bouldin
University of Mississippi Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marshall J. Bouldin.
Hypertension | 2005
Vasilios Kotsis; Stella Stabouli; Marshall J. Bouldin; Annette K. Low; Savvas Toumanidis; N. Zakopoulos
The purpose of the present study was to determine the relationship between body mass index (BMI) and parameters derived from 24-hour ambulatory blood pressure monitoring including mean 24-hour daytime and nighttime systolic and diastolic blood pressures, 24-hour daytime and nighttime pulse pressure, mean 24-hour daytime and nighttime heart rate, dipping and nondipping status. 3216 outpatient subjects who visited our hypertension center and were never treated with antihypertensive medication underwent 24-hour blood pressure monitoring. BMI was significantly correlated with clinic systolic and diastolic blood pressures. Significant correlations were also found between BMI and mean 24-hour daytime and nighttime systolic blood pressure, 24-hour daytime and nighttime pulse pressure, and mean 24-hour daytime and nighttime heart rate. In multivariate regression analysis, clinic systolic, diastolic blood pressure, mean 24-hour systolic blood pressure, 24-hour pulse pressure, and high-density lipoprotein were independently correlated with BMI. The incidence of white coat hypertension was higher in overweight and obese patients than in normal weight subjects. Confirmed ambulatory blood pressure hypertension was also found to be higher in overweight and obese individuals compared with normal weight subjects. Our data also highlight the higher incidence of nondipping status in obesity. These findings suggest that obese patients had increased ambulatory blood pressure parameters and altered circadian blood pressure rhythm with increased prevalence of nondipping status.
The American Journal of the Medical Sciences | 2006
Marshall J. Bouldin; Leigh Ann Ross; Caryl D. Sumrall; Fleetwood V. Loustalot; Annette K. Low; Kelly K. Land
Obesity is epidemic in the modern world. It is becoming increasingly clear that obesity is a major cause of cardiovascular disease, diabetes, and renal disease, as well as a host of other comorbidities. There are at present no generally effective long-term medical therapies for obesity. Surgical therapy for morbid obesity is not only effective in producing long-term weight loss but is also effective in ameliorating or resolving several of the most significant complications of obesity, including diabetes, hypertension, dyslipidemia, sleep apnea, gastroesophageal reflux disease, degenerative joint disease, venous stasis, pseudotumor cerebri, nonalcoholic steatohepatitis, urinary incontinence, fertility problems, and others. The degree of benefit and the rates of morbidity and mortality of the various surgical procedures vary according to the procedure.
The American Journal of the Medical Sciences | 2006
Annette K. Low; Marshall J. Bouldin; Caryl D. Sumrall; Fleetwood V. Loustalot; Kelly K. Land
Obesity is pandemic in the modern world and continues to increase at an alarming rate, with great human and economic consequences. While bariatric surgery has been gaining popularity and acceptance as an effective way to achieve massive weight loss, it remains an option only for the extremely obese. For the millions of overweight and moderately obese individuals, the cornerstone of obesity treatment remains lifestyle and behavioral modifications in diet and physical activity. It is especially important for both primary care providers and subspecialists to be familiar with currently recommended approaches to the medical treatment of obesity, as it is critical that this extremely common, treatable chronic disease be recognized, intervention initiated, and therapy maintained at every appropriate clinical opportunity. Significant medical benefits can be gained even with a relatively small percentage of weight loss.
The American Journal of the Medical Sciences | 2002
Marshall J. Bouldin; Annette K. Low; Joseph W. Blackston; David N. Duddleston; Honey E. Holman; G. Swink Hicks; C. Andrew Brown
We are in the midst of a global pandemic of diabetes. Despite the increasing burden of the disease, measurements of quality repeatedly show poor adherence to or implementation of current guidelines for diabetes care. This article will provide a brief review of the most significant randomized controlled clinical trials relevant to the current guidelines and then discuss essential treatment goals and the evidence that supports them. Several practical clinical questions related to the implementation of modern diabetes guidelines will be raised and answered. Finally, reasons for the poor quality performance observed will be examined.
The American Journal of the Medical Sciences | 2002
C. Andrew Brown; Marshall J. Bouldin; Joseph W. Blackston; David N. Duddleston; Jinna M. Shepherd; Gilliam S. Hicks
Primary aldosteronism (PA) is a disorder typically characterized by resistant hypertension, hypokalemia, alkalosis and suppressed plasma renin activity, and excessive aldosterone production. A true estimate of the prevalence of the disorder is difficult to estimate because its detection is dependent on the awareness of the healthcare provider to the disorder, but it has generally been felt to be a rare occurrence. Its frequency of detection began to change when Hiramatsu suggested calculating the ratio of plasma aldosterone/plasma renin activity as a screening tool for the disorder. He found a ratio greater than 75 as a sensitive indicator for aldosterone-producing adenomas. Using the ratio, several investigators have found prevalence ranging from 3 to 9%. Two major classifications of PA exist: aldosterone-producing adrenal adenoma (APA) and zona glomerulosa hyperplasia (IHA). Distinguishing between these 2 entities is important clinically, because removal of a unilateral aldosterone-producing adenoma may result in correction of elevated blood pressure and hypokalemia. Thus, when evaluating hypertensive patients, PA should be suspected in those with moderate to severe hypertension or with hypertension refractory to standard treatment or in hypertensive patients with disease onset at an early age. The aldosterone-to-renin ratio is an easy, inexpensive, and rapid means of screening for the disorder. The ratio is the screening test of choice, but further confirmatory testing is required to clinch the diagnosis. Frequently employed confirmatory tests include urinary aldosterone excretion on a high-salt diet, aldosterone suppression after a saline infusion, and the fludrocortisone suppression test, which is considered the most sensitive confirmatory maneuver. Both high-resolution CT and MRI scans appear to have similar ability to differentiate between APA and IHA. As with essential hypertension, the goal of treatment is to prevent the long-term sequela of hypertension. The underlying pathology resulting in PA dictates the treatment strategy. The drug of choice is spironolactone. Surgical intervention should be entertained in those patients with PA in whom imaging studies suggest an adenoma.
The American Journal of the Medical Sciences | 2002
Joseph W. Blackston; Marshall J. Bouldin; C. Andrew Brown; David N. Duddleston; G. Swink Hicks; Honey E. Holman
&NA; The recent medical malpractice “crisis” has seen skyrocketing liability premiums and increasing fear of liability. Primary care physicians, especially family medicine and internal medicine physicians, have historically experienced low rates of malpractice claims, both in number and amount of payment. This can be attributed to several factors: the esteem held by internal medicine and family medicine physicians in their communities, relatively low numbers of invasive procedures, reluctance of patients to include “their” primary care physician in any potential litigation, and, probably most importantly, the atmosphere of mutual trust and communication between the internist or family physician and the patient. Recent years have seen this trend erased, as insurance industry data suggest primary care physicians presently face significant potential exposure for medical malpractice claims. It is imperative that primary care physicians take steps to insure they are adequately covered in case of a malpractice claim and that they practice aggressive but appropriate risk management to lessen the likelihood of a claim.
The American Journal of the Medical Sciences | 2002
David N. Duddleston; Joseph W. Blackston; Marshall J. Bouldin; C. Andrew Brown
Disability income protection is an important part of a workers safety net. U.S. workers who pay into Social Security are eligible for coverage under the federal government, and additional coverage is available in the free market. However, the costs to taxpayers and disability insurance policyholders are high, and a great deal of responsibility rests on the physician providing information on disability issues. A neutral attitude toward a patient requesting disability allows the physician to collect the facts regarding the patients impairments. A history of the patients work duties helps the examiner determine the basis for setting limitations or restrictions at work or home. The physicians knowledge base of treatment options assists in determining maximal medical improvement. Records released to the adjudicating body should contain a thorough history, pertinent physical findings, and a review of previous medical records, all of which are to be separated from the opinion of the examiner regarding specific limitations and restrictions. The physician should be aware of symptom magnification and depression as confounders to the patients perception of disability.
The American Journal of the Medical Sciences | 2002
Honey E. Holman; G. Swink Hicks; Annette K. Low; Marshall J. Bouldin; Lori D. Russell; Christopher A. Friedrich; C. Andrew Brown
&NA; Coronary heart disease (CHD) remains the leading cause of death in the United States. It is now well established that cholesterol is an important, reversible risk factor for CHD. This article provides a brief background on classification of the dyslipidemias, then discusses current recommendations for the evaluation and treatment of hyperlipidemia. Other risk factors currently being investigated as they relate to the development of CHD are discussed.
Ethnicity & Disease | 2007
Annette K. Low; Karen B. Grothe; Taylor S. Wofford; Marshall J. Bouldin
The Lancet | 2002
Annette K. Low; Marshall J. Bouldin